Fulcrum Therapeutics, Inc. FULC
We take great care to ensure that the data presented and summarized in this overview for Fulcrum Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FULC
View all-
Rtw Investments, LP New York, NY5.85MShares$45.4 Million0.89% of portfolio
-
Cowen And Company, LLC3.71MShares$28.9 Million1.18% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.85MShares$22.1 Million1.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$19.7 Million0.0% of portfolio
-
Trv Gp Iv, LLC Boston, MA2.34MShares$18.2 Million10.72% of portfolio
-
Black Rock Inc. New York, NY1.54MShares$12 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.33MShares$10.3 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.3MShares$10.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.16MShares$8.99 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY1.15MShares$8.95 Million0.11% of portfolio
Latest Institutional Activity in FULC
Top Purchases
Top Sells
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at FULC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 07
2024
|
Greg Tourangeau Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
236
-2.0%
|
$1,652
$7.76 P/Share
|
|
Mar 08
2024
|
Greg Tourangeau Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,884
-29.26%
|
$53,724
$11.72 P/Share
|
|
Mar 04
2024
|
Alex Sapir |
BUY
Open market or private purchase
|
Direct |
43,360
+50.0%
|
$476,960
$11.35 P/Share
|
|
May 10
2023
|
Greg Tourangeau Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
210
-1.3%
|
$630
$3.31 P/Share
|
|
Jan 20
2023
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,923,076
+14.21%
|
$24,999,988
$13.0 P/Share
|
|
Jan 13
2023
|
Robert J Gould Interim President & CEO |
SELL
Open market or private sale
|
Direct |
6,766
-1.34%
|
$101,490
$15.0 P/Share
|
|
Jan 04
2023
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
180,703
+0.93%
|
$1,264,921
$7.42 P/Share
|
|
Dec 27
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,089
+0.04%
|
$20,445
$5.99 P/Share
|
|
Dec 19
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
98,787
+1.03%
|
$493,935
$5.9 P/Share
|
|
Dec 16
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,341,420
+12.48%
|
$6,707,100
$5.42 P/Share
|
|
Dec 15
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
237,029
+2.86%
|
$1,185,145
$5.5 P/Share
|
|
Dec 14
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
824,600
+9.53%
|
$4,123,000
$5.46 P/Share
|
|
Dec 13
2022
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-50.48%
|
-
|
|
Jun 07
2022
|
Robert J Gould Interim President & CEO |
SELL
Open market or private sale
|
Direct |
71,435
-12.36%
|
$571,480
$8.09 P/Share
|
|
Jun 07
2022
|
Robert J Gould Interim President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
71,435
+11.0%
|
$500,045
$7.84 P/Share
|
|
Jun 06
2022
|
Robert J Gould Interim President & CEO |
SELL
Open market or private sale
|
Direct |
24,382
-4.59%
|
$195,056
$8.1 P/Share
|
|
Jun 06
2022
|
Robert J Gould Interim President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,382
+4.39%
|
$170,674
$7.84 P/Share
|
|
Jun 03
2022
|
Robert J Gould Interim President & CEO |
SELL
Open market or private sale
|
Direct |
25,551
-4.8%
|
$178,857
$7.95 P/Share
|
|
Jun 03
2022
|
Robert J Gould Interim President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,551
+4.58%
|
$178,857
$7.84 P/Share
|
|
Jun 02
2022
|
Robert J Gould Interim President & CEO |
SELL
Open market or private sale
|
Direct |
16,689
-3.19%
|
$116,823
$7.92 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 43.4K shares |
|---|
| Open market or private sale | 5.12K shares |
|---|